TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06373549

Intervention type: PROCEDURE
Intervention: Patients with coronary artery bypass surgery routine procedural administration of cardioplegia solutions
Description: To investigate the effectiveness of myocardial protection methods, blood samples were collected from the coronary sinus before the aortic cross-clamping and at 4 minutes after aortic cross-clamping, through a coronary sinus cannula with a yellow-capped gel tube. The collected blood samples were kept in an upright position for 20 minutes to allow separation into serum fraction, then centrifuged at 3000 g for 10 minutes (Beckman Coulter, Microfuge 16, USA). The obtained serums were aliquoted into 250 μl portions in Eppendorf tubes, separately for each patient.

Intervention type: PROCEDURE
Intervention: Patients with coronary artery bypass surgery routine procedural administration of cardioplegia solutions
Description: To investigate the effectiveness of myocardial protection methods, blood samples were collected from the coronary sinus before the aortic cross-clamping and at 4 minutes after aortic cross-clamping, through a coronary sinus cannula with a yellow-capped gel tube. The collected blood samples were kept in an upright position for 20 minutes to allow separation into serum fraction, then centrifuged at 3000 g for 10 minutes (Beckman Coulter, Microfuge 16, USA). The obtained serums were aliquoted into 250 μl portions in Eppendorf tubes, separately for each patient.

Intervention type: PROCEDURE
Intervention: Patients who underwent heart valve surgery without coronary artery disease routine procedural administration of cardioplegia solutions
Description: To investigate the effectiveness of myocardial protection methods, blood samples were collected from the coronary sinus before the aortic cross-clamping and at 4 minutes after aortic cross-clamping, through a coronary sinus cannula with a yellow-capped gel tube. The collected blood samples were kept in an upright position for 20 minutes to allow separation into serum fraction, then centrifuged at 3000 g for 10 minutes (Beckman Coulter, Microfuge 16, USA). The obtained serums were aliquoted into 250 μl portions in Eppendorf tubes, separately for each patient.

Intervention type: PROCEDURE
Intervention: Patients who underwent heart valve surgery without coronary artery disease routine procedural administration of cardioplegia solutions
Description: To investigate the effectiveness of myocardial protection methods, blood samples were collected from the coronary sinus before the aortic cross-clamping and at 4 minutes after aortic cross-clamping, through a coronary sinus cannula with a yellow-capped gel tube. The collected blood samples were kept in an upright position for 20 minutes to allow separation into serum fraction, then centrifuged at 3000 g for 10 minutes (Beckman Coulter, Microfuge 16, USA). The obtained serums were aliquoted into 250 μl portions in Eppendorf tubes, separately for each patient.
Study: NCT05761171

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and CSF samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and CSF samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study: NCT04706923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCV
Description: Brincidofovir (BCV) is a lipid conjugate of the antiviral cidofovir that enables optimal intracellular levels of the active drug.
Study: NCT05761171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV and IT
Study: NCT04706923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCV
Description: Brincidofovir (BCV) is a lipid conjugate of the antiviral cidofovir that enables optimal intracellular levels of the active drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCV
Description: Brincidofovir (BCV) is a lipid conjugate of the antiviral cidofovir that enables optimal intracellular levels of the active drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCV
Description: Brincidofovir (BCV) is a lipid conjugate of the antiviral cidofovir that enables optimal intracellular levels of the active drug.
Study: NCT06454942

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrient-fortified egg
Description: Consumption of nutrient-fortified eggs with habitual diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Regular egg with habitual diet
Description: Consumption of regular egg with habitual diet
Study: NCT06402071

Intervention type: DIAGNOSTIC_TEST
Intervention: Ascitic fluid study
Description: Ascitic fluid study will be obtained from all participants

Intervention type: DIAGNOSTIC_TEST
Intervention: Ascitic fluid study
Description: Ascitic fluid study will be obtained from all participants
Study: NCT05761171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV and IT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT
Study: NCT05670782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KM-819
Description: Participants will receive oral doses of KM-819 once-daily
Study: NCT06197971

Intervention type: OTHER
Group type: OTHER
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: Graston Technique instruments to apply strokes and movements along the length of the muscle fibers. Sweeping strokes, cross-fiber friction, and circular motions patterns will be applied on hamstring muscles.

Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic Cupping Technique
Description: Stationary cupping technique will be used for a duration of 5-15 minutes with multiple Silicone Cups applied on the Hamstrings.
Study: NCT04920552

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elastic abdominal binder
Description: The ABDO-SYNCRO 3-BAHNIG is an elastic abdominal binder with a 3-stripes Velcro fastening, capable of developing a 20 ± 2 mmHg pressure on the abdominal wall. This device will be tested as potentially beneficial with respect to the mentioned primary and secondary outcomes. The investigators anticipate to use this elastic abdominal binder, since participants of a previous trial reported this device to be comfortable enough and to have used it regularly during the open-label follow-up phase. Size will be chosen depending on the abdominal circumference of the participant, according to the size tables provided from the manufacturer (SYNCRO-MED GmbH).
Study: NCT05670782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KM-819
Description: Participants will receive oral doses of KM-819 once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KM-819
Description: Participants will receive oral doses of KM-819 once-daily
Study: NCT04920552

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Elastic abdominal binder
Description: The ABDO-SYNCRO 3-BAHNIG is an elastic abdominal binder with a 3-stripes Velcro fastening, capable of developing a 20 ± 2 mmHg pressure on the abdominal wall. This device will be tested as potentially beneficial with respect to the mentioned primary and secondary outcomes. The investigators anticipate to use this elastic abdominal binder, since participants of a previous trial reported this device to be comfortable enough and to have used it regularly during the open-label follow-up phase. Size will be chosen depending on the abdominal circumference of the participant, according to the size tables provided from the manufacturer (SYNCRO-MED GmbH).
Study: NCT04920552

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo binder
Description: Clima Care is a simple body warmer, developing maximal 3±2 mmHg pressure on the abdominal wall. This device will be used as placebo comparator of the present clinical trial. Size will be chosen depending on the abdominal circumference of the participant, according to the size tables provided from the manufacturer.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo binder
Description: Clima Care is a simple body warmer, developing maximal 3±2 mmHg pressure on the abdominal wall. This device will be used as placebo comparator of the present clinical trial. Size will be chosen depending on the abdominal circumference of the participant, according to the size tables provided from the manufacturer.
Study: NCT05478369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: storybook
Description: anxiety and fear during operative
Study: NCT05761171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO or via NG, NJ, ND or G-tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or via NG, NJ, ND or G-tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Given PO or via NG, NJ, ND or G-tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Given PO or via NG, NJ, ND or G-tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT04815564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign
Description: Invisalign clear aligner system
Study: NCT05670782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KM-819
Description: Participants will receive oral doses of KM-819 once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo once-daily
Study: NCT04572282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mentora app
Description: Remote monitoring mobile app
Study: NCT04562311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide: 30mg orally BIW. Immunotherapy: tislelizumab,the fixed dose of 200 mg IV. Treatment cycles are repeated every 3 weeks.
Study: NCT05943262

Intervention type: DEVICE
Intervention: mesoscale nonlinear optical microscope
Description: The mesoscale nonlinear optical microscope based on the principles of nonlinear optics and computed-algorithms can acquire large-area image within few minutes.
Study: NCT05000216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273
Description: Administration: One dose administered intramuscularly.
Study: NCT05954702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supercharged TRAM esophagectomy
Description: Esophagectomy, immediately followed by supercharged esophagogastroplasty. Use the transverse rectus abdominis myocutaneous (TRAM) flap transfers to surgically create a new anastomosis in the left gastroepiploic vessels.
Study: NCT05000216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Administration: One dose administered intramuscularly.
Study: NCT05954702

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Esophagectomy
Description: Esophagectomy, immediately followed by an esophagus reconstruction trough esophagogastroplasty.
Study: NCT05092646

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axolotl Ambient
Description: Axolotl Ambient is an allogeneic amniotic intra-articular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug/Placebo: 0.9% Normal Saline
Description: Drug/Placebo: 0.9% Normal Saline
Study: NCT06177314

Intervention type: OTHER
Intervention: correlate the molecular signatures of active lesions of contact dermatitis with allergological results
Description: Data will be collected retrospectively and prospectively from patients' medical records, and will include: clinical information (history, treatments, lifestyle, exposures, lesion location and appearance), patch-test results, histological analysis results, molecular analysis results.
Study: NCT04978064

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: e-health psychological counselling
Description: Intervention group: Women positive for IPV who accept the e-Health intervention and who have been randomly allocated in the intervention group will receive the e-health package as the rest of the cohort, as well as the baseline and outcome measurements. The e-health package will include six video counselling sessions by trained providers and the access to a mobile application for designing security plans, an adapted version of the mobile application My Plan. The content of the six individually tailored sessions will be based on the Dutton's Empowerment Model and the Psychosocial Readiness Model.~Control group: women positive in IPV who accept the e-Health intervention package will be asked for a second consent to receive a delayed intervention (8 weeks later) and to complete as the baseline and outcome measurements. Women can request to leave the control group at any time and to receive the intervention immediately (in which case they data will be part of the cohort study).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-health psychological counselling
Description: Intervention group: Women positive for IPV who accept the e-Health intervention and who have been randomly allocated in the intervention group will receive the e-health package as the rest of the cohort, as well as the baseline and outcome measurements. The e-health package will include six video counselling sessions by trained providers and the access to a mobile application for designing security plans, an adapted version of the mobile application My Plan. The content of the six individually tailored sessions will be based on the Dutton's Empowerment Model and the Psychosocial Readiness Model.~Control group: women positive in IPV who accept the e-Health intervention package will be asked for a second consent to receive a delayed intervention (8 weeks later) and to complete as the baseline and outcome measurements. Women can request to leave the control group at any time and to receive the intervention immediately (in which case they data will be part of the cohort study).
Study: NCT05000216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Administration: One dose administered intramuscularly.
Study: NCT05738694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib plus Toripalimab
Description: Preoperative treatment with axitinib will be given for 3 months, 5 mg twice daily, orally. Preoperative treatment with Toripalimab will be given for 4 cycles (3 weeks considered one cycle), 240 mg, Q3W.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nephrectomy
Description: nephrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nephrectomy
Description: nephrectomy
Study: NCT05000216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Administration: One dose administered intramuscularly.
Study: NCT06441136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PhoRTE Program
Description: Speech therapy program guided by a speech language pathologist. This program includes in person or virtual visits and at home exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: University of California Los Angeles (UCLA) Loneliness Scale
Description: A questionnaire measuring levels of loneliness.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Disconnectedness Scale
Description: A questionnaire that asks about social network size and the frequency of social activities attended.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire 9
Description: A questionnaire measuring levels of depression.
Study: NCT05000216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Administration: One dose administered intramuscularly.
Study: NCT06441136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aging Voice Index
Description: A questionnaire of patient-reported voice outcome measures designed to capture the quality of life impact of dysphonia in older adults.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Edmonton Frail Scale
Description: A questionnaire that measures frailty levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vocal Effort Scale
Description: A picture based questionnaire scale that asks the subject to rate their perceived effort when using their voice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment
Description: A screening tool used to test for cognitive impairment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voice Handicap Index-10
Description: A questionnaire used to measure quality of life impact of dysphonia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voice Problem Impact Scales
Description: A 4 question survey that captures impact of voice on four domains - work/daily activities, social life, home, and overall quality of life.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cough Severity Index
Description: A 10 question survey asking to rate severity of cough.
Study: NCT06441136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy
Description: Nose is anesthetized and a flexible endoscope is passed to visualize the larynx at rest and during sustained vowel production (/i/) for 3-5 seconds. This will be used to measure bowing index and normalized glottal gap of the vocal folds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acoustic, perceptual, and aerodynamic assessments
Description: Participants will complete voice recording tasks including sustained vowel production, six standard sentences, and 20 seconds of natural conversational speech. This will be used to measure CAPE-V rating, Cepstral peak prominence, fundamental frequency, signal-to-noise ratio, voice type components, mean flow rate, subglottal pressure, and vocal efficiency.
Study: NCT05000216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continue IS (MMF or MPA)
Description: Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continue IS (MMF or MPA)
Description: Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continue IS (MMF or MPA)
Description: Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.
Study: NCT05720455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCL and pseudoephedrine HCL
Description: Extended-Release Tablets
Study: NCT04562116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Nemolizumab 30 mg will be administered as SC injections.
Study: NCT05000216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continue IS (MMF or MPA)
Description: Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.